Disrupting of IGF2BP3-stabilized CLDN11 mRNA by TNF-α increases intestinal permeability in obesity-related severe

Lihui Lin1, Yansong Lin2, Xianwen Guo1

  • 1Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, P. R. China.

Abstract

Insights

Claudin 11 (CLDN11) helps regulate intestinal permeability in obesity-related severe acute pancreatitis (SAP). Tumor necrosis factor-alpha (TNF-α) disrupts this by reducing CLDN11 mRNA stability, leading to increased intestinal permeability and pancreatitis.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Pathophysiology

Background:

  • Obesity is a key risk factor for severe acute pancreatitis (SAP), often linked to increased intestinal permeability.
  • Claudin 11 (CLDN11), a tight junction protein, influences barrier function, but its role in obesity-related SAP intestinal permeability is unknown.

Purpose of the Study:

  • To investigate the role and mechanism of CLDN11 in intestinal permeability during obesity-related SAP.
  • To explore the potential of targeting the CLDN11 pathway for therapeutic intervention.

Main Methods:

  • Evaluated intestinal permeability and CLDN11 expression in experimental obesity-related SAP models.
  • Utilized recombinant adeno-associated virus for CLDN11 manipulation and assessed its effects.
  • Investigated the interaction between CLDN11 mRNA and IGF2BP3 protein using bioinformatics and experimental validation.
  • Examined the impact of tumor necrosis factor-alpha (TNF-α) on the IGF2BP3/CLDN11 axis in Caco-2 cells and in vivo.

Main Results:

  • CLDN11 expression was downregulated in intestinal epithelial cells of experimental obesity-related SAP.
  • Exogenous CLDN11 restoration reduced intestinal epithelial permeability and pancreatic inflammation.
  • Overexpression of CLDN11 decreased paracellular permeability, while knockdown increased it.
  • IGF2BP3 was identified as a regulator of CLDN11 mRNA stability.
  • TNF-α downregulated both IGF2BP3 and CLDN11; anti-TNFα therapy improved intestinal barrier function and reduced pancreatitis.

Conclusions:

  • CLDN11 plays a crucial role in regulating intestinal permeability in obesity-related SAP.
  • Increased TNF-α impairs the stability of IGF2BP3-dependent CLDN11 mRNA, contributing to the pathophysiology of obesity-related SAP.

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
69
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
332
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
176